Preparing for the incoming wave of biosimilars in oncology.

With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency.

[Unusual complications after radical cystectomy]. / Complicaciones inusuales post-cistectomía radical.

OBJECTIVES: To report complications that are very rare in patients undergoing radical cystectomy and Bricker's ileal conduit. In accordance to the literature and our own experience, to remark the importance of a proper preoperative preparation (nutritional, preanesthetic evaluation...), and adequate postoperative controls to avoid this kind of problems. METHODS: We report three cases which are demonstrative of these complications, their main characteristics, as well as their diagnosis, treatment, and outcomes. RESULTS: All three cases were complicated by fistulae, with different outcomes. The diagnostic measures undertook on each one are reviewed in detail. Although it is well shown in the literature that most of these fistulae appear in patients with intestinal inflammatory/infectious diseases, this was not our experience. CONCLUSIONS: After a bibliographic review and study of our cases, we insist on the importance of a good nutritional evaluation before surgery, and that radical cystectomy with Bricker's type urinary diversion, although consolidated as treatment for infiltrative bladder cancer, is not exempt of immediate postoperative complications or even deferred, as in our case.